New 'Quad-Specific' antibody tackles tough leukemia
NCT ID NCT05944978
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called GNC-035, a tetra-specific antibody, in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and other blood cancers. The study aims to find a safe dose and check for side effects. Only 3 participants have been enrolled so far, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GNC-035 tetra-specific antibody
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat chronic lymphocytic leukemia.
- What could go wrong
- This is a very early, tiny trial (only 3 participants) focused on safety and dosing. It is too soon to know if it will be effective, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill outsmart Treatment-Resistant blood cancer?
- Experimental immune therapy takes on tough lymphomas
- New cell therapy takes aim at Hard-to-Treat blood cancers
- New hope for tough blood cancers: early trial of ONO-7018 begins
- Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers
- New shot for tough blood cancers enters first human tests